Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Onivyde Clear all
Withdrawn Phase 1Phase 2 Interventional

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT03739801
View directory record Official record
Conditions
Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Liposomal Irinotecan, Quality-of-Life Assessment, Questionnaire Administration, Ramucirumab
Drug · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Phase I Trial HIPEC With Nal-irinotecan

NCT04088786
View directory record Official record
Conditions
Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor, Colorectal Cancer, Gastric Cancer, Primary Peritoneal Carcinoma, Mesothelioma
Interventions
nanoliposomal irinotecan
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Lexington, Kentucky • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 3, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

NCT06835387
View directory record Official record
Conditions
Small Bowel Adenocarcinoma
Interventions
Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil, Leucovorin
Drug
Lead sponsor
Tiago Biachi de Castria
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Tampa, Florida • Chicago, Illinois • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 3, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

Folfox+Irinotecan+Chemort In Esophageal Cancer

NCT04656041
View directory record Official record
Conditions
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Interventions
FOLFOX/ nal-IRI, Paclitaxel, Carboplatin, Proton Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 3, 2026, 2:33 AM EDT
Withdrawn Early Phase 1 Interventional

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

NCT03554707
View directory record Official record
Conditions
Childhood CNS Tumor
Interventions
SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
Genetic · Radiation · Drug
Lead sponsor
SynerGene Therapeutics, Inc.
Industry
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

NCT01926197
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 3, 2026, 2:33 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
Setidegrasib, Oxaliplatin, Leucovorin, Irinotecan, fluorouracil, liposomal irinotecan, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
49
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

NCT03368963
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients

NCT02826486
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BL-8040, Pembrolizumab, Chemotherapy
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 3, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

NCT04005339
View directory record Official record
Conditions
Advanced Biliary Tract Cancer
Interventions
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

NCT03785873
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • Salt Lake City, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

NCT03086616
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 3, 2026, 2:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

NCT03483038
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Liposomal Irinotecan, FOLFOX regimen
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Gainesville, Florida • Orlando, Florida • Tallahassee, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

NCT03883919
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

NCT03861702
View directory record Official record
Conditions
Locally Advanced Pancreatic Carcinoma(LAPC)
Interventions
FOLFOX regimen, Liposomal Irinotecan
Drug
Lead sponsor
Nelson Yee
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

NCT00364143
View directory record Official record
Conditions
Cancer
Interventions
IHL-305 (irinotecan liposome injection)
Drug
Lead sponsor
Yakult Honsha Co., LTD
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

NCT04083235
View directory record Official record
Conditions
Metastatic Adenocarcinoma of the Pancreas
Interventions
Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil, Leucovorin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

NCT07076212
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil, Leucovorin, Gemcitabine (mg/m²), Nab-paclitaxel, Cisplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

NCT02231723
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

NCT03207724
View directory record Official record
Conditions
Pancreatic Cancer, Cachexia, Weight Loss
Interventions
Xilonix plus Onivyde and 5FU
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

NCT02551991
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
29
States / cities
Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 3, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas

NCT00734682
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Interventions
Nanoliposomal CPT-11
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 3, 2026, 2:33 AM EDT